GLAXO2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member GLAXO2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2019-04-01 2020-03-31 2020-05-11 INR Lakhs Yearly Single segment Pharmaceuticals 2020-01-01 2020-03-31 Unaudited Consolidated 7758033000.00 158177000.00 7916210000.00 983289000.00 2012847000.00 -201512000.00 1715845000.00 15075000.00 225852000.00 1511972000.00 6263368000.00 1652842000.00 112679000.00 1765521000.00 579325000.00 -194507000.00 384818000.00 0.00 1380703000.00 0.00 0.00 0.00 0.00 1380703000.00 5355000.00 1386058000.00 1386028000.00 0.00 1694100000.00 10 8.15 8.15 0.00 0.00 8.15 8.15 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 18th May, 2020.The statutory auditors have not issued a separate limited review report on the results for the quarter ended March 31, 2019.  n n2. Effective 1st April, 2019, the Group adopted Ind AS 116 “Leases” and applied the same to the lease contracts existing on 1st April, 2019 using the modified retrospective approach, recognizing right-of-use asset and adjusted lease liability. Accordingly, comparatives for the year ended 31st March, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the result for the period(s). n n3. Exceptional items for the year ended 31st March 2020 Rs.34149 lakhs ( year ended 31st March 2019 Rs.2869 lakhs) mainly comprise of : na) impacts following the decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India by the Ultimate Holding Company and the comprehensive strategic review of the impact of this recall on all related assets in India: ni. financial impairment of Rs.63743 Lacs (including cost to sell) (year ended 31st March 2019 – Rs. Nil) connected to the under-utilisation of its manufacturing facilities and Rs.9563 Lacs (year ended 31st March 2019 Rs. Nil) on account of other related assets / cost nii. Provisions on account of product recall of Zinetac Rs.10809 lakhs (year ended 31st March 2019 – Rs. Nil) nb) Profit on sale of property Rs. 54630 lakhs (year ended 31st March 2019 Rs. 4339 Lakhs) nc) Others Rs. 4664 Lacs (year ended 31st March 2019 Rs.1470 Lacs) n nExceptional items for the quarter ended 31st March 2020 Rs 1127 lakhs (Quarter ended 31st March 2019 Rs. 1992 lakhs) mainly comprise of: na)treversal of expense due to settlement/ change in estimate Rs.1127 lakhs (Quarter ended 31st March 2019 Rs Nil) nb)tincome from sale of property Rs. Nil (Quarter ended 31st March 2019 Rs 1992 Lacs) n n4. The Parent has elected to exercise the option permitted u/s 115BAA of the Income- tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019. Accordingly, the Parent has recognised Provision for Income tax for the year ended 31st March, 2020 and re-measured its net Deferred Tax Assets basis the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit and Loss for the year ended 31st March, 2020. Tax expense includes charge on account of exceptional items Rs. 1757 Lakhs, prior year charge of Rs. 2486 Lakhs and impact on net deferred tax due to change in tax rates Rs. 1692 Lakhs of which Rs.50 Lakhs is accounted in Other Comprehensive Income. n nBalance Notes from 5 to 9 have been inserted in Tab Assets Liabilities under- Disclosure of notes on assets and liabilities - Add Notes Single segment 2019-04-01 2020-03-31 Audited Consolidated 32243807000.00 790074000.00 33033881000.00 4743797000.00 8689228000.00 -354327000.00 6285535000.00 63355000.00 826777000.00 6307104000.00 26561469000.00 6472412000.00 -3414931000.00 3057481000.00 2601708000.00 -476223000.00 2125485000.00 0.00 931996000.00 0.00 0.00 0.00 0.00 931996000.00 -39773000.00 892223000.00 892243000.00 0.00 1694100000.00 10 16511989000.00 5.50 5.50 0.00 0.00 5.50 5.50 Other Expenses 1511972000.00 Other Expenses 6307104000.00